Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 4/2009

01.08.2009 | Review

Large neutral amino acids supplementation in phenylketonuric patients

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Summary

Phenylketonuria is an inborn error of amino acid metabolism that results in severe mental retardation if not treated early and appropriately. The traditional treatment, consisting of a low-phenylalanine diet, is usually difficult to maintain throughout adolescence and adulthood, resulting in undesirable levels of blood phenylalanine and consequent neurotoxicity. The neurotoxicity of phenylalanine is enhanced by its transport mechanism across the blood-brain barrier, which has the highest affinity for phenylalanine compared with the other large neutral amino acids that share the same carrier. The supplementation of large neutral amino acids in phenylketonuric patients has been showing interesting results. Plasma phenylalanine levels can be reduced, which may guarantee important metabolic and clinical benefits to these patients. Although long-term studies are needed to determine the efficacy and safety of large neutral amino acids supplements, the present state of knowledge seems to recommend their prescription to all phenylketonuric adult patients who are non-compliant with the low-phenylalanine diet.
Literatur
Zurück zum Zitat Berger V, Larondelle Y, Trouet A, Schneider YJ (2000) Transport mechanisms of the large neutral amino acid L-phenylalanine in the human intestinal epithelial caco-2 cell line. J Nutr 130: 2780–2788PubMed Berger V, Larondelle Y, Trouet A, Schneider YJ (2000) Transport mechanisms of the large neutral amino acid L-phenylalanine in the human intestinal epithelial caco-2 cell line. J Nutr 130: 2780–2788PubMed
Zurück zum Zitat Binek-Singer P, Johnson TC (1982) The effects of chronic hyperphenylalaninaemia on mouse brain protein synthesis can be prevented by other amino acids. Biochem J 206: 407–414PubMed Binek-Singer P, Johnson TC (1982) The effects of chronic hyperphenylalaninaemia on mouse brain protein synthesis can be prevented by other amino acids. Biochem J 206: 407–414PubMed
Zurück zum Zitat Blows WT (2000) Neurotransmitters of the brain: serotonin, noradrenaline (norepinephrine), and dopamine. J Neurosci Nurs 32: 234–238PubMed Blows WT (2000) Neurotransmitters of the brain: serotonin, noradrenaline (norepinephrine), and dopamine. J Neurosci Nurs 32: 234–238PubMed
Zurück zum Zitat Burlina AB, Bonafe L, Ferrari V, Suppiej A, Zacchello F, Burlina AP (2000) Measurement of neurotransmitter metabolites in the cerebrospinal fluid of phenylketonuric patients under dietary treatment. J Inherit Metab Dis 23: 313–316. doi:10.1023/A:1005694122277 PubMedCrossRef Burlina AB, Bonafe L, Ferrari V, Suppiej A, Zacchello F, Burlina AP (2000) Measurement of neurotransmitter metabolites in the cerebrospinal fluid of phenylketonuric patients under dietary treatment. J Inherit Metab Dis 23: 313–316. doi:10.​1023/​A:​1005694122277 PubMedCrossRef
Zurück zum Zitat Dotremont H, Francois B, Diels M, Gillis P (1995) Nutritional value of essential amino acids in the treatment of adults with phenylketonuria. J Inherit Metab Dis 18: 127–130. doi:10.1007/BF00711746 PubMedCrossRef Dotremont H, Francois B, Diels M, Gillis P (1995) Nutritional value of essential amino acids in the treatment of adults with phenylketonuria. J Inherit Metab Dis 18: 127–130. doi:10.​1007/​BF00711746 PubMedCrossRef
Zurück zum Zitat Griffiths P, Paterson L, Harvie A (1995) Neuropsychological effects of subsequent exposure to phenylalanine in adolescents and young adults with early-treated phenylketonuria. J Intellect Disabil Res 39(Pt 5): 365–372PubMedCrossRef Griffiths P, Paterson L, Harvie A (1995) Neuropsychological effects of subsequent exposure to phenylalanine in adolescents and young adults with early-treated phenylketonuria. J Intellect Disabil Res 39(Pt 5): 365–372PubMedCrossRef
Zurück zum Zitat Guttler F, Lou H (1986) Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function. J Inherit Metab Dis 9(Supplement 2): 169–177. doi:10.1007/BF01799701 PubMedCrossRef Guttler F, Lou H (1986) Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function. J Inherit Metab Dis 9(Supplement 2): 169–177. doi:10.​1007/​BF01799701 PubMedCrossRef
Zurück zum Zitat Hawkins RA, O’Kane RL, Simpson IA, Vina JR (2006) Structure of the blood-brain barrier and its role in the transport of amino acids. J Nutr 136: 218S–226SPubMed Hawkins RA, O’Kane RL, Simpson IA, Vina JR (2006) Structure of the blood-brain barrier and its role in the transport of amino acids. J Nutr 136: 218S–226SPubMed
Zurück zum Zitat Hoeksma M, Reijngoud DJ, Pruim J, de Valk HW, Paans AM, van Spronsen FJ (2009) Phenylketonuria: high plasma phenylalanine decreases cerebral protein synthesis. Mol Genet Metab 96(4): 177–182. Epub 2009 Feb 6PubMedCrossRef Hoeksma M, Reijngoud DJ, Pruim J, de Valk HW, Paans AM, van Spronsen FJ (2009) Phenylketonuria: high plasma phenylalanine decreases cerebral protein synthesis. Mol Genet Metab 96(4): 177–182. Epub 2009 Feb 6PubMedCrossRef
Zurück zum Zitat Huether G, Neuhoff V, Kaus R (1983) Brain development in experimental hyperphenylalaninaemia: disturbed proliferation and reduced cell numbers in the cerebellum. Neuropediatrics 14: 12–19. doi:10.1055/s-2008-1059547 PubMedCrossRef Huether G, Neuhoff V, Kaus R (1983) Brain development in experimental hyperphenylalaninaemia: disturbed proliferation and reduced cell numbers in the cerebellum. Neuropediatrics 14: 12–19. doi:10.​1055/​s-2008-1059547 PubMedCrossRef
Zurück zum Zitat Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H (1998) Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273: 23629–23632. doi:10.1074/jbc.273.37.23629 PubMedCrossRef Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H (1998) Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273: 23629–23632. doi:10.​1074/​jbc.​273.​37.​23629 PubMedCrossRef
Zurück zum Zitat Karasov W, Solberg D, Carter S, et al (1986) Uptake pathways for amino acids in mouse intestine. Am J Physiol 251: G501–508PubMed Karasov W, Solberg D, Carter S, et al (1986) Uptake pathways for amino acids in mouse intestine. Am J Physiol 251: G501–508PubMed
Zurück zum Zitat Knudsen GM, Hasselbalch S, Toft PB, Christensen E, Paulson OB, Lou H (1995) Blood-brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria. J Inherit Metab Dis 18: 653–664. doi:10.1007/BF02436753 PubMedCrossRef Knudsen GM, Hasselbalch S, Toft PB, Christensen E, Paulson OB, Lou H (1995) Blood-brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria. J Inherit Metab Dis 18: 653–664. doi:10.​1007/​BF02436753 PubMedCrossRef
Zurück zum Zitat Kreis R, Pietz J, Penzien J, Herschkowitz N, Boesch C (1995) Identification and quantitation of phenylalanine in the brain of patients with phenylketonuria by means of localized in vivo 1H magnetic-resonance spectroscopy. J Magn Reson B 107: 242–251. doi:10.1006/jmrb.1995.1084 PubMedCrossRef Kreis R, Pietz J, Penzien J, Herschkowitz N, Boesch C (1995) Identification and quantitation of phenylalanine in the brain of patients with phenylketonuria by means of localized in vivo 1H magnetic-resonance spectroscopy. J Magn Reson B 107: 242–251. doi:10.​1006/​jmrb.​1995.​1084 PubMedCrossRef
Zurück zum Zitat Mastroberardino L, Spindler B, Pfeiffer R, et al (1998) Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature 395: 288–291. doi:10.1038/26246 PubMedCrossRef Mastroberardino L, Spindler B, Pfeiffer R, et al (1998) Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature 395: 288–291. doi:10.​1038/​26246 PubMedCrossRef
Zurück zum Zitat Matalon KM (2001) Developments in phenylketonuria. Top Clin Nutr 16: 41–50 Matalon KM (2001) Developments in phenylketonuria. Top Clin Nutr 16: 41–50
Zurück zum Zitat Matalon R, Michals-Matalon K, Bhatia G, et al (2007) Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine. J Inherit Metab Dis 30: 153–158. doi:10.1007/s10545-007-0556-4 PubMedCrossRef Matalon R, Michals-Matalon K, Bhatia G, et al (2007) Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine. J Inherit Metab Dis 30: 153–158. doi:10.​1007/​s10545-007-0556-4 PubMedCrossRef
Zurück zum Zitat Moats RA, Moseley KD, Koch R, Nelson M Jr (2003) Brain phenylalanine concentrations in phenylketonuria: research and treatment of adults. Pediatrics 112: 1575–1579PubMed Moats RA, Moseley KD, Koch R, Nelson M Jr (2003) Brain phenylalanine concentrations in phenylketonuria: research and treatment of adults. Pediatrics 112: 1575–1579PubMed
Zurück zum Zitat Munck BG, Munck LK (1994) Phenylalanine transport in rabbit small intestine. J Physiol 480(Pt 1): 99–107PubMed Munck BG, Munck LK (1994) Phenylalanine transport in rabbit small intestine. J Physiol 480(Pt 1): 99–107PubMed
Zurück zum Zitat O’Kane RL, Hawkins RA (2003) Na+-dependent transport of large neutral amino acids occurs at the abluminal membrane of the blood-brain barrier. Am J Physiol Endocrinol Metab 285: E1167–1173PubMed O’Kane RL, Hawkins RA (2003) Na+-dependent transport of large neutral amino acids occurs at the abluminal membrane of the blood-brain barrier. Am J Physiol Endocrinol Metab 285: E1167–1173PubMed
Zurück zum Zitat O’Kane RL, Vina JR, Simpson I, Hawkins RA (2004) Na+-dependent neutral amino acid transporters A, ASC, and N of the blood-brain barrier: mechanisms for neutral amino acid removal. Am J Physiol Endocrinol Metab 287: E622–629. doi:10.1152/ajpendo.00187.2004 PubMedCrossRef O’Kane RL, Vina JR, Simpson I, Hawkins RA (2004) Na+-dependent neutral amino acid transporters A, ASC, and N of the blood-brain barrier: mechanisms for neutral amino acid removal. Am J Physiol Endocrinol Metab 287: E622–629. doi:10.​1152/​ajpendo.​00187.​2004 PubMedCrossRef
Zurück zum Zitat Ohtsuki S, Terasaki T (2007) Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 24: 1745–1758. doi:10.1007/s11095-007-9374-5 PubMedCrossRef Ohtsuki S, Terasaki T (2007) Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 24: 1745–1758. doi:10.​1007/​s11095-007-9374-5 PubMedCrossRef
Zurück zum Zitat Pietz J, Kreis R, Boesch C, Penzien J, Rating D, Herschkowitz N (1995) The dynamics of brain concentrations of phenylalanine and its clinical significance in patients with phenylketonuria determined by in vivo 1H magnetic resonance spectroscopy. Pediatr Res 38: 657–663. doi:10.1203/00006450-199511000-00005 PubMedCrossRef Pietz J, Kreis R, Boesch C, Penzien J, Rating D, Herschkowitz N (1995) The dynamics of brain concentrations of phenylalanine and its clinical significance in patients with phenylketonuria determined by in vivo 1H magnetic resonance spectroscopy. Pediatr Res 38: 657–663. doi:10.​1203/​00006450-199511000-00005 PubMedCrossRef
Zurück zum Zitat Pietz J, Kreis R, Rupp A, et al (1999) Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest 103: 1169–1178. doi:10.1172/JCI5017 PubMedCrossRef Pietz J, Kreis R, Rupp A, et al (1999) Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest 103: 1169–1178. doi:10.​1172/​JCI5017 PubMedCrossRef
Zurück zum Zitat Rocha JC, Vilarinho L, Cabral A, Vaz Osório R, de Almeida MF (2007) Consensus for the nutritional treatment of phenylketonuria. Acta Pediatr Port 38: 44–54 Rocha JC, Vilarinho L, Cabral A, Vaz Osório R, de Almeida MF (2007) Consensus for the nutritional treatment of phenylketonuria. Acta Pediatr Port 38: 44–54
Zurück zum Zitat Sanchez del Pino MM, Hawkins RA, Peterson DR (1992) Neutral amino acid transport by the blood-brain barrier. Membrane vesicle studies. J Biol Chem 267: 25951–25957PubMed Sanchez del Pino MM, Hawkins RA, Peterson DR (1992) Neutral amino acid transport by the blood-brain barrier. Membrane vesicle studies. J Biol Chem 267: 25951–25957PubMed
Zurück zum Zitat Sarkissian CN, Gámez A, Scriver CR (2009) What we know that could influence future treatment of phenylketonuria. J Inherit Metab Dis 32(1): 3–9. Epub 2008 Aug 3PubMedCrossRef Sarkissian CN, Gámez A, Scriver CR (2009) What we know that could influence future treatment of phenylketonuria. J Inherit Metab Dis 32(1): 3–9. Epub 2008 Aug 3PubMedCrossRef
Zurück zum Zitat Schmidt E, Rupp A, Burgard P, Pietz J, Weglage J, de Sonneville L (1994) Sustained attention in adult phenylketonuria: the influence of the concurrent phenylalanine-blood-level. J Clin Exp Neuropsychol 16: 681–688. doi:10.1080/01688639408402681 PubMedCrossRef Schmidt E, Rupp A, Burgard P, Pietz J, Weglage J, de Sonneville L (1994) Sustained attention in adult phenylketonuria: the influence of the concurrent phenylalanine-blood-level. J Clin Exp Neuropsychol 16: 681–688. doi:10.​1080/​0168863940840268​1 PubMedCrossRef
Zurück zum Zitat Scriver CR, Kaufman S (2001) Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 1667–1724 Scriver CR, Kaufman S (2001) Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 1667–1724
Zurück zum Zitat Smith QR (2000) Transport of glutamate and other amino acids at the blood-brain barrier. J Nutr 130: 1016S–1022SPubMed Smith QR (2000) Transport of glutamate and other amino acids at the blood-brain barrier. J Nutr 130: 1016S–1022SPubMed
Zurück zum Zitat van Calcar SC, MacLeod EL, Gleason ST, et al (2009) Improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acids. Am J Clin Nutr 89(4): 1068–1077. Epub 2009 Feb 25PubMedCrossRef van Calcar SC, MacLeod EL, Gleason ST, et al (2009) Improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acids. Am J Clin Nutr 89(4): 1068–1077. Epub 2009 Feb 25PubMedCrossRef
Zurück zum Zitat van Meer G, Simons K (1986) The function of tight junctions in maintaining differences in lipid composition between the apical and the basolateral cell surface domains of MDCK cells. EMBO J 5: 1455–1464PubMed van Meer G, Simons K (1986) The function of tight junctions in maintaining differences in lipid composition between the apical and the basolateral cell surface domains of MDCK cells. EMBO J 5: 1455–1464PubMed
Zurück zum Zitat Walter JH, Lee PJ, Burgard P (2006) Hyperphenylalaninaemia. In Fernandes J, Saudubray J-M, van den Berghe G, Walter JH, eds. Inborn Metabolic Diseases. Heidelberg: Springer, 221–232CrossRef Walter JH, Lee PJ, Burgard P (2006) Hyperphenylalaninaemia. In Fernandes J, Saudubray J-M, van den Berghe G, Walter JH, eds. Inborn Metabolic Diseases. Heidelberg: Springer, 221–232CrossRef
Zurück zum Zitat Weglage J, Wiedermann D, Denecke J, et al (2001) Individual blood-brain barrier phenylalanine transport determines clinical outcome in phenylketonuria. Ann Neurol 50: 463–467. doi:10.1002/ana.1226 PubMedCrossRef Weglage J, Wiedermann D, Denecke J, et al (2001) Individual blood-brain barrier phenylalanine transport determines clinical outcome in phenylketonuria. Ann Neurol 50: 463–467. doi:10.​1002/​ana.​1226 PubMedCrossRef
Metadaten
Titel
Large neutral amino acids supplementation in phenylketonuric patients
Publikationsdatum
01.08.2009
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe 4/2009
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-009-1132-x

Weitere Artikel der Ausgabe 4/2009

Journal of Inherited Metabolic Disease 4/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.